The P-IIIa (ONWARDS 2) trial evaluating insulin icodec (qw) vs insulin degludec (qd) in 526 patients with T2D
The trial met its 1EPs & showed non-inferiority in reducing HbA1c, 37% vs 27% of adults achieved an HbA1c <7.0% without experiencing sev. or clinically significant hypoglycaemia @26wks., 8.17% (icodec) & 8.10% (degludec) for insulin icodec achieved a superior reduction in estimated HbA1c of 0.93% vs 0.71% for insulin degludec, patients also achieved greater treatment satisfaction when switching to insulin icodec (qw)
The mean weekly insulin dose was 268 vs 244U/wk. while the mean change in body weight from baseline to 26wk. was 1.40kg vs –0.30kg along with the safe & well-tolerated profile with no sev. hypoglycaemia events
Ref: Novo Nordisk | Image: Novo Nordisk
